中樞神經系統合作研究與授權交易：2019-2024

本報告調查了中樞神經系統的聯合研究和授權交易，並提供了自2019年以來的合約趨勢、中樞神經系統的聯合研究和授權交易、基準分析- 交易的市場價值、財務狀況和關鍵資訊。

目錄

執行摘要

第1章 - 簡介

第2章 中樞神經系統交易趨勢

• 簡介
• 中樞神經系統的長期合作趨勢
• 中樞神經系統合作，依交易類型
• 中樞神經系統合作，依產業部門
• 中樞神經系統合作，依開發階段
• 中樞神經系統合作，依技術類型
• 中樞神經系統合作，依治療適應症

第3章 - 有關中樞神經系統夥伴關係的金融交易條件

• 簡介
• 已公佈的中樞神經系統合作夥伴關係的財務條款
• 中樞神經系統聯盟的標題值
• 中樞神經系統交易預付款
• 中樞神經系統交易的里程碑付款
• 中樞神經系統交易的特許權使用費率

第4章 －主要中樞神經系統交易與交易人員

• 簡介
• 與中樞神經系統的合作最為活躍
• 中樞神經系統中最活躍的交易撮合者名單
• 中樞神經系統中的主要交易

第5章 - 中樞神經系統合約文件目錄

• 簡介
• 可簽約的中樞神經系統合作夥伴交易

第6章 依治療目標劃分的中樞神經系統交易

• 簡介
• 以中樞神經系統治療標靶進行的交易
• 交易目錄
• 貿易目錄 - 中樞神經系統交易，依公司劃分（2019-2024年）
• 貿易目錄 - 中樞神經系統交易，依技術類型劃分（2019-2024年）
• 交易類型的定義
• 關於Biopharma Research Ltd
• 目前的合作關係
• 當前合約
• Current Partnering的最新報告標題

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 946 central nervous system deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse central nervous system collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

• Trends in central nervous system dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of central nervous system deal records covering pharmaceutical and biotechnology
• The leading central nervous system deals by value
• Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Central nervous system partnering by deal type
• 2.4. Central nervous system partnering by industry sector
• 2.5. Central nervous system partnering by stage of development
• 2.6. Central nervous system partnering by technology type
• 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for central nervous system partnering
• 3.3. Central nervous system partnering headline values
• 3.4. Central nervous system deal upfront payments
• 3.5. Central nervous system deal milestone payments
• 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in central nervous system partnering
• 4.3. List of most active dealmakers in central nervous system
• 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

• 5.1. Introduction
• 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by central nervous system therapeutic target
• Deal Directory
• Deal Directory - Central nervous system deals by company A-Z 2019 to 2024
• Deal Directory - Central nervous system deals by technology type 2019 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Central nervous system partnering since 2019
• Figure 2: Central nervous system partnering by deal type since 2019
• Figure 3: Central nervous system partnering by industry sector since 2019
• Figure 4: Central nervous system partnering by stage of development since 2019
• Figure 5: Central nervous system partnering by technology type since 2019
• Figure 6: Central nervous system partnering by indication since 2019
• Figure 7: Central nervous system deals with a headline value
• Figure 8: Central nervous system deals with upfront payment values
• Figure 9: Central nervous system deals with milestone payment
• Figure 10: Central nervous system deals with royalty rates
• Figure 11: Active central nervous system dealmaking activity since 2019
• Figure 12: Top central nervous system deals by value since 2019